Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 249

1.

Perceptions of the Cause, Impact and Management of Persistent Fatigue in Patients with Rheumatoid Arthritis Following Tumour Necrosing Factor Inhibition Therapy.

Minnock P, Ringnér A, Bresnihan B, Veale D, FitzGerald O, McKee G.

Musculoskeletal Care. 2017 Mar;15(1):23-35. doi: 10.1002/msc.1136. Epub 2016 Feb 12.

PMID:
26871999
2.

Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysis.

Minnock P, Veale DJ, Bresnihan B, FitzGerald O, McKee G.

Clin Rheumatol. 2015 Nov;34(11):1857-65. doi: 10.1007/s10067-015-3088-6. Epub 2015 Oct 9.

3.

How much is fatigue explained by standard clinical characteristics of disease activity in patients with inflammatory arthritis? A longitudinal study.

Minnock P, McKee G, Bresnihan B, FitzGerald O, Veale DJ.

Arthritis Care Res (Hoboken). 2014 Nov;66(11):1597-603. doi: 10.1002/acr.22387.

4.

Differential expression of NK receptors CD94 and NKG2A by T cells in rheumatoid arthritis patients in remission compared to active disease.

Walsh CE, Ryan EJ, O'Farrelly C, Golden-Mason L, FitzGerald O, Veale DJ, Bresnihan B, Fearon U.

PLoS One. 2011;6(11):e27182. doi: 10.1371/journal.pone.0027182. Epub 2011 Nov 15.

5.

Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy.

Connolly M, Mullan RH, McCormick J, Matthews C, Sullivan O, Kennedy A, FitzGerald O, Poole AR, Bresnihan B, Veale DJ, Fearon U.

Arthritis Rheum. 2012 Apr;64(4):1035-45. doi: 10.1002/art.33455. Epub 2011 Nov 10.

6.

The impact of a revised EQ-5D population scoring on preference-based utility scores in an inflammatory arthritis cohort.

Adams R, Craig BM, Walsh CD, Veale DJ, Bresnihan B, FitzGerald O, Barry M.

Value Health. 2011 Sep-Oct;14(6):921-7. doi: 10.1016/j.jval.2011.03.002. Epub 2011 Jul 8.

7.

Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy--a single centre, open-label study.

Pontifex EK, Gerlag DM, Gogarty M, Vinkenoog M, Gibbs A, Burgman I, Fearon U, Bresnihan B, Tak PP, Gibney RG, Veale DJ, FitzGerald O.

Arthritis Res Ther. 2011 Jan 27;13(1):R7. doi: 10.1186/ar3228.

8.

Pulmonary fibrosis in systemic sclerosis: association with myocardial fibrosis.

Nicholson PJ, Hegarty C, Jackson M, Keane D, Fitzgerald O, Bresnihan B, Veale D, Dodd JD.

J Thorac Imaging. 2012 Jan;27(1):44-50. doi: 10.1097/RTI.0b013e3181fbf8c1.

PMID:
21107283
9.

CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial.

van Kuijk AW, Vergunst CE, Gerlag DM, Bresnihan B, Gomez-Reino JJ, Rouzier R, Verschueren PC, van der Leij C, Maas M, Kraan MC, Tak PP.

Ann Rheum Dis. 2010 Nov;69(11):2013-6. doi: 10.1136/ard.2010.131235. Epub 2010 Aug 6. Erratum in: Ann Rheum Dis. 2013 Apr;72(4):630. van de Leij, Christiaan [corrected to van der Leij, Christiaan].

PMID:
20693270
10.

Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis.

Minnock P, Kirwan J, Veale D, Fitzgerald O, Bresnihan B.

Clin Exp Rheumatol. 2010 May-Jun;28(3):401-4. Epub 2010 Jun 23.

PMID:
20525443
11.

Remission in psoriatic arthritis: is it possible and how can it be predicted?

Saber TP, Ng CT, Renard G, Lynch BM, Pontifex E, Walsh CA, Grier A, Molloy M, Bresnihan B, Fitzgerald O, Fearon U, Veale DJ.

Arthritis Res Ther. 2010;12(3):R94. doi: 10.1186/ar3021. Epub 2010 May 18.

12.

Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis.

Adams R, Walsh C, Veale D, Bresnihan B, FitzGerald O, Barry M.

Pharmacoeconomics. 2010;28(6):477-87. doi: 10.2165/11533010-000000000-00000.

PMID:
20465316
13.

Synovial tissue hypoxia and inflammation in vivo.

Ng CT, Biniecka M, Kennedy A, McCormick J, Fitzgerald O, Bresnihan B, Buggy D, Taylor CT, O'Sullivan J, Fearon U, Veale DJ.

Ann Rheum Dis. 2010 Jul;69(7):1389-95. doi: 10.1136/ard.2009.119776. Epub 2010 May 3.

14.

Acute serum amyloid A induces migration, angiogenesis, and inflammation in synovial cells in vitro and in a human rheumatoid arthritis/SCID mouse chimera model.

Connolly M, Marrelli A, Blades M, McCormick J, Maderna P, Godson C, Mullan R, FitzGerald O, Bresnihan B, Pitzalis C, Veale DJ, Fearon U.

J Immunol. 2010 Jun 1;184(11):6427-37. doi: 10.4049/jimmunol.0902941. Epub 2010 Apr 30.

15.

A role for the high-density lipoprotein receptor SR-B1 in synovial inflammation via serum amyloid-A.

Mullan RH, McCormick J, Connolly M, Bresnihan B, Veale DJ, Fearon U.

Am J Pathol. 2010 Apr;176(4):1999-2008. doi: 10.2353/ajpath.2010.090014. Epub 2010 Mar 19.

16.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.

Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dörner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH, Winthrop K.

Ann Rheum Dis. 2010 Jan;69 Suppl 1:i2-29. doi: 10.1136/ard.2009.123885. No abstract available. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
19995740
17.

Unregulated prescribing of anti-tumour necrosis factor agents does not mean inappropriate prescribing.

Ng CT, Radovits BJ, Kievit W, Fransen J, van Riel PL, FitzGerald O, Veale DJ, Bresnihan B.

Ann Rheum Dis. 2010 Jan;69(1):313-4. doi: 10.1136/ard.2009.107748. No abstract available.

PMID:
20007623
18.

Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade.

Rooney T, Edwards CK 3rd, Gogarty M, Greenan L, Veale DJ, FitzGerald O, Dayer JM, Bresnihan B.

Rheumatol Int. 2010 Nov;30(12):1571-80. doi: 10.1007/s00296-009-1191-1. Epub 2009 Oct 22.

PMID:
19847430
19.

Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis.

Minnock P, Kirwan J, Bresnihan B.

Rheumatology (Oxford). 2009 Dec;48(12):1533-6. doi: 10.1093/rheumatology/kep287. Epub 2009 Sep 22.

PMID:
19773406
20.

EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis.

Zhang W, Doherty M, Peat G, Bierma-Zeinstra MA, Arden NK, Bresnihan B, Herrero-Beaumont G, Kirschner S, Leeb BF, Lohmander LS, Mazières B, Pavelka K, Punzi L, So AK, Tuncer T, Watt I, Bijlsma JW.

Ann Rheum Dis. 2010 Mar;69(3):483-9. doi: 10.1136/ard.2009.113100. Epub 2009 Sep 17. Review.

PMID:
19762361

Supplemental Content

Loading ...
Support Center